Kevin  Feeley net worth and biography

Kevin Feeley Biography and Net Worth

CFO of GeneDx

Kevin Feeley has more than 20 years of finance and accounting leadership experience in the healthcare, pharmaceutical, and diagnostics sectors. As Chief Financial Officer at GeneDx, Kevin leads financial strategy, management, and planning. Kevin is also responsible for key operational aspects of the company, including lab network operations, supply chain, and genetic counseling services.

Previously, Kevin served as Chief Financial Officer of OPKO Health’s rapidly growing diagnostics division for six years, which included BioReference Laboratories, Inc. and GeneDx. During the COVID-19 pandemic, Kevin led the operational design and execution of BioReference’s sports diagnostic program serving all four major sports leagues in the U.S.

Before that, Kevin was U.S. Controller at Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene, and nutrition brands. He also previously led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company, and spent twelve years in the audit practice of KPMG LLP working closely with large multinational pharmaceutical companies.

Kevin is a Certified Public Accountant and holds a BBA in Accounting from James Madison University.

What is Kevin Feeley's net worth?

The estimated net worth of Kevin Feeley is at least $608.45 thousand as of October 29th, 2025. Mr. Feeley owns 3,757 shares of GeneDx stock worth more than $608,446 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Feeley may own. Additionally, Mr. Feeley receives an annual salary of $488,190.00 as CFO at GeneDx. Learn More about Kevin Feeley's net worth.

How old is Kevin Feeley?

Mr. Feeley is currently 43 years old. There are 1 older executives and no younger executives at GeneDx. The oldest executive at GeneDx is Ms. Katherine A. Stueland, President, CEO & Director, who is 48 years old. Learn More on Kevin Feeley's age.

What is Kevin Feeley's salary?

As the CFO of GeneDx Holdings Corp., Mr. Feeley earns $488,190.00 per year. The highest earning executive at GeneDx is Ms. Katherine A. Stueland, President, CEO & Director, who commands a salary of $745,910.00 per year. Learn More on Kevin Feeley's salary.

How do I contact Kevin Feeley?

The corporate mailing address for Mr. Feeley and other GeneDx executives is 333 Ludlow Street North Tower 8th Floor, Stamford CT, 06902. GeneDx can also be reached via phone at 800-298-6470 and via email at [email protected]. Learn More on Kevin Feeley's contact information.

Has Kevin Feeley been buying or selling shares of GeneDx?

In the last ninety days, Kevin Feeley has sold $52,977.52 of GeneDx stock. Most recently, Kevin Feeley sold 388 shares of the business's stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $136.54, for a transaction totalling $52,977.52. Following the completion of the sale, the chief financial officer now directly owns 3,757 shares of the company's stock, valued at $512,980.78. Learn More on Kevin Feeley's trading history.

Who are GeneDx's active insiders?

GeneDx's insider roster includes Shawn Assad (CAO), Daniel Clark (General Counsel), James Coffin (COO), Kevin Feeley (CFO), Keith Meister (Director), Richard Pfenniger, Jr. (Director), Richard Pfenniger, Jr. (Director), Anthony Prentice (Insider), Isaac Ro (CFO), Jason Ryan (Chairman of the Board), Eric Schadt (CEO), and Katherine Stueland (CEO). Learn More on GeneDx's active insiders.

Are insiders buying or selling shares of GeneDx?

In the last year, GeneDx insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $5,601,000.00. In the last year, insiders at the sold shares 38 times. They sold a total of 883,497 shares worth more than $100,107,549.19. The most recent insider tranaction occured on November, 24th when Director Joshua Ruch sold 38,000 shares worth more than $6,094,060.00. Insiders at GeneDx own 29.6% of the company. Learn More about insider trades at GeneDx.

Information on this page was last updated on 11/24/2025.

Kevin Feeley Insider Trading History at GeneDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/29/2025Sell388$136.54$52,977.523,757View SEC Filing Icon  
9/16/2025Sell3,728$121.47$452,840.168,755View SEC Filing Icon  
9/2/2025Sell378$125.81$47,556.184,096View SEC Filing Icon  
7/29/2025Sell388$105.31$40,860.283,757View SEC Filing Icon  
7/9/2025Sell5,278$93.00$490,854.003,392View SEC Filing Icon  
7/1/2025Sell1,344$91.12$122,465.287,425View SEC Filing Icon  
6/2/2025Sell370$71.26$26,366.204,105View SEC Filing Icon  
4/29/2025Sell388$113.09$43,878.923,337View SEC Filing Icon  
4/9/2025Sell15,516$92.18$1,430,264.881,726View SEC Filing Icon  
3/26/2025Sell8,746$95.61$836,205.0615,996View SEC Filing Icon  
3/17/2025Sell3,749$96.71$362,565.798,492View SEC Filing Icon  
3/13/2025Sell402$90.05$36,200.105,044View SEC Filing Icon  
3/10/2025Sell922$94.72$87,331.845,446View SEC Filing Icon  
1/29/2025Sell275$78.48$21,582.002,950View SEC Filing Icon  
1/7/2025Sell35,506$93.82$3,331,172.922,472View SEC Filing Icon  
1/2/2025Sell1,430$76.04$108,737.2026,770View SEC Filing Icon  
12/16/2024Sell3,728$76.75$286,124.0028,200View SEC Filing Icon  
12/9/2024Sell1,137$76.37$86,832.6924,731View SEC Filing Icon  
12/2/2024Sell263$78.39$20,616.5723,406View SEC Filing Icon  
11/21/2024Sell12,019$73.76$886,521.4432,932View SEC Filing Icon  
10/29/2024Sell274$66.60$18,248.4044,951View SEC Filing Icon  
9/9/2024Sell895$33.33$29,830.3539,910View SEC Filing Icon  
9/3/2024Sell262$31.71$8,308.0238,343View SEC Filing Icon  
7/29/2024Sell274$33.54$9,189.9637,888View SEC Filing Icon  
6/17/2024Sell2,646$28.31$74,908.2637,409View SEC Filing Icon  
6/10/2024Sell895$24.92$22,303.4032,858View SEC Filing Icon  
4/29/2024Sell1,104$11.04$12,188.1630,836View SEC Filing Icon  
3/18/2024Sell3,253$10.59$34,449.2728,927View SEC Filing Icon  
12/18/2023Sell2,948$2.16$6,367.6823,035View SEC Filing Icon  
12/4/2023Sell270$1.77$477.9017,232View SEC Filing Icon  
9/18/2023Sell2,742$4.16$11,406.7216,785View SEC Filing Icon  
9/11/2023Sell904$4.62$4,176.4812,330View SEC Filing Icon  
9/5/2023Sell269$4.38$1,178.2210,772View SEC Filing Icon  
6/20/2023Sell2,744$6.37$17,479.2810,324View SEC Filing Icon  
6/13/2023Sell903$6.49$5,860.475,871View SEC Filing Icon  
6/2/2023Sell263$7.00$1,841.004,312View SEC Filing Icon  
5/16/2023Sell1,516$6.50$9,854.003,856View SEC Filing Icon  
3/10/2023Sell965$11.88$11,464.202,359View SEC Filing Icon  
12/2/2022Sell256$13.20$3,379.20460View SEC Filing Icon  
See Full Table

Kevin Feeley Buying and Selling Activity at GeneDx

This chart shows Kevin Feeley's buying and selling at GeneDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GeneDx Company Overview

GeneDx logo
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More

Today's Range

Now: $161.95
Low: $158.99
High: $164.22

50 Day Range

MA: $134.11
Low: $107.74
High: $167.51

2 Week Range

Now: $161.95
Low: $55.17
High: $170.87

Volume

246,312 shs

Average Volume

489,080 shs

Market Capitalization

$4.68 billion

P/E Ratio

1,799.44

Dividend Yield

N/A

Beta

1.99